Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 141

1.

Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, Schittenhelm J, Schuhmann MU, Tatagiba M, Marquardt G, Wagner M, Endris V, Brandts CH, Mautner VF, Schröck E, Weichert W, Brors B, von Deimling A, Mittelbronn M, Steinbach JP, Reuss DE, Glimm H, Stenzinger A, Fröhling S.

J Clin Invest. 2020 Feb 4. pii: 130787. doi: 10.1172/JCI130787. [Epub ahead of print]

2.

Delayed Occurrence of Hypertrophic Olivary Degeneration after Therapy of Posterior Fossa Tumors: A Single Institution Retrospective Analysis.

Schaller-Paule MA, Foerch C, Kluge S, Baumgarten P, Konczalla J, Steinbach JP, Wagner M, Luger AL.

J Clin Med. 2019 Dec 16;8(12). pii: E2222. doi: 10.3390/jcm8122222.

3.

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.

Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, Senft C, Tonn T, Steinbach JP, Wels WS.

Front Immunol. 2019 Nov 14;10:2683. doi: 10.3389/fimmu.2019.02683. eCollection 2019. Review.

4.

Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

Zeiner PS, Kinzig M, Divé I, Maurer GD, Filipski K, Harter PN, Senft C, Bähr O, Hattingen E, Steinbach JP, Sörgel F, Voss M, Steidl E, Ronellenfitsch MW.

J Clin Med. 2019 Nov 21;8(12). pii: E2031. doi: 10.3390/jcm8122031.

5.

Delay in diagnosing patients with right-sided glioblastoma induced by hemispheric-specific clinical presentation.

Baumann C, Tichy J, Schaefer JH, Steinbach JP, Mittelbronn M, Wagner M, Foerch C.

J Neurooncol. 2020 Jan;146(1):63-69. doi: 10.1007/s11060-019-03335-4. Epub 2019 Nov 11.

PMID:
31713017
6.

Adrenal Insufficiency in Patients with Corticosteroid-Refractory Cerebral Radiation Necrosis Treated with Bevacizumab.

Voss M, Batarfi A, Steidl E, Wagner M, Forster MT, Steinbach JP, Rödel CM, Bojunga J, Ronellenfitsch MW.

J Clin Med. 2019 Oct 3;8(10). pii: E1608. doi: 10.3390/jcm8101608.

7.

Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.

Di Tacchio M, Macas J, Weissenberger J, Sommer K, Bähr O, Steinbach JP, Senft C, Seifert V, Glas M, Herrlinger U, Krex D, Meinhardt M, Weyerbrock A, Timmer M, Goldbrunner R, Deckert M, Scheel AH, Büttner R, Grauer OM, Schittenhelm J, Tabatabai G, Harter PN, Günther S, Devraj K, Plate KH, Reiss Y.

Cancer Immunol Res. 2019 Dec;7(12):1910-1927. doi: 10.1158/2326-6066.CIR-18-0865. Epub 2019 Oct 9.

PMID:
31597643
8.

18F-FET PET imaging in differentiating glioma progression from treatment-related changes - a single-center experience.

Maurer GD, Brucker DP, Stoffels G, Filipski K, Filss CP, Mottaghy FM, Galldiks N, Steinbach JP, Hattingen E, Langen KJ.

J Nucl Med. 2019 Sep 13. pii: jnumed.119.234757. doi: 10.2967/jnumed.119.234757. [Epub ahead of print]

PMID:
31519802
9.

Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.

Heinzen D, Divé I, Lorenz NI, Luger AL, Steinbach JP, Ronellenfitsch MW.

Int J Mol Sci. 2019 Sep 10;20(18). pii: E4474. doi: 10.3390/ijms20184474.

10.

Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial.

Weller J, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Hau P, Krex D, Grauer O, Goldbrunner R, Bähr O, Uhl M, Seidel C, Tabatabai G, Brehmer S, Bullinger L, Galldiks N, Schaub C, Kebir S, Stummer W, Simon M, Fimmers R, Coch C, Glas M, Herrlinger U, Schäfer N.

Lancet Oncol. 2019 Oct;20(10):1444-1453. doi: 10.1016/S1470-2045(19)30502-9. Epub 2019 Sep 2.

PMID:
31488360
11.

EGFR and mTOR as therapeutic targets in glioblastoma.

Ronellenfitsch MW, Luger AL, Steinbach JP.

Oncotarget. 2019 Jul 30;10(46):4721-4723. doi: 10.18632/oncotarget.27094. eCollection 2019 Jul 30. No abstract available.

12.

Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial.

Kebir S, Schaub C, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Galldiks N, Weller J, Mack F, Tzaridis T, Bähr O, Seidel C, Schlegel U, Schmidt-Graf F, Rohde V, Borchers C, Tabatabai G, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Glas M, Herrlinger U.

J Neurooncol. 2019 Sep;144(3):501-509. doi: 10.1007/s11060-019-03246-4. Epub 2019 Jul 19.

PMID:
31325144
13.

Loss of cell-matrix contact increases hypoxia-inducible factor-dependent transcriptional activity in glioma cells.

Maurer GD, Brucker DP, Steinbach JP.

Biochem Biophys Res Commun. 2019 Jul 12;515(1):77-84. doi: 10.1016/j.bbrc.2019.05.115. Epub 2019 May 23.

PMID:
31128911
14.

Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas.

Filipski K, Braun Y, Zinke J, Roller B, Baumgarten P, Wagner M, Senft C, Zeiner PS, Ronellenfitsch MW, Steinbach JP, Plate KH, Gasparoni G, Mittelbronn M, Capper D, Harter PN.

Acta Neuropathol. 2019 Aug;138(2):331-334. doi: 10.1007/s00401-019-02025-9. Epub 2019 May 7. No abstract available.

15.

Knockdown of the TP53-Induced Glycolysis and Apoptosis Regulator (TIGAR) Sensitizes Glioma Cells to Hypoxia, Irradiation and Temozolomide.

Maurer GD, Heller S, Wanka C, Rieger J, Steinbach JP.

Int J Mol Sci. 2019 Mar 1;20(5). pii: E1061. doi: 10.3390/ijms20051061.

16.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
17.

The physiological mTOR complex 1 inhibitor DDIT4 mediates therapy resistance in glioblastoma.

Foltyn M, Luger AL, Lorenz NI, Sauer B, Mittelbronn M, Harter PN, Steinbach JP, Ronellenfitsch MW.

Br J Cancer. 2019 Mar;120(5):481-487. doi: 10.1038/s41416-018-0368-3. Epub 2019 Feb 12.

18.

Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.

Voss M, Franz K, Steinbach JP, Fokas E, Forster MT, Filipski K, Hattingen E, Wagner M, Breuer S.

J Neurooncol. 2019 Mar;142(1):161-169. doi: 10.1007/s11060-018-03076-w. Epub 2019 Jan 2.

PMID:
30604393
19.

Disruption of peroxisome proliferator-activated receptor γ coactivator (PGC)-1α reverts key features of the neoplastic phenotype of glioma cells.

Bruns I, Sauer B, Burger MC, Eriksson J, Hofmann U, Braun Y, Harter PN, Luger AL, Ronellenfitsch MW, Steinbach JP, Rieger J.

J Biol Chem. 2019 Mar 1;294(9):3037-3050. doi: 10.1074/jbc.RA118.006993. Epub 2018 Dec 21.

PMID:
30578297
20.

Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.

Zeiner PS, Preusse C, Golebiewska A, Zinke J, Iriondo A, Muller A, Kaoma T, Filipski K, Müller-Eschner M, Bernatz S, Blank AE, Baumgarten P, Ilina E, Grote A, Hansmann ML, Verhoff MA, Franz K, Feuerhake F, Steinbach JP, Wischhusen J, Stenzel W, Niclou SP, Harter PN, Mittelbronn M.

Brain Pathol. 2019 Jul;29(4):513-529. doi: 10.1111/bpa.12690. Epub 2019 Jan 15.

21.

Fitting algorithms and baseline correction influence the results of non-invasive in vivo quantitation of 2-hydroxyglutarate with 1 H-MRS.

Wenger KJ, Hattingen E, Harter PN, Richter C, Franz K, Steinbach JP, Bähr O, Pilatus U.

NMR Biomed. 2019 Jan;32(1):e4027. doi: 10.1002/nbm.4027. Epub 2018 Nov 20.

PMID:
30457203
22.

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma.

Ronellenfitsch MW, Zeiner PS, Mittelbronn M, Urban H, Pietsch T, Reuter D, Senft C, Steinbach JP, Westphal M, Harter PN.

Acta Neuropathol Commun. 2018 Aug 21;6(1):81. doi: 10.1186/s40478-018-0583-4.

23.

Rescue of 2-Deoxyglucose Side Effects by Ketogenic Diet.

Voss M, Lorenz NI, Luger AL, Steinbach JP, Rieger J, Ronellenfitsch MW.

Int J Mol Sci. 2018 Aug 20;19(8). pii: E2462. doi: 10.3390/ijms19082462.

24.

Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases.

Burger MC, Wagner M, Franz K, Harter PN, Bähr O, Steinbach JP, Senft C.

J Clin Med. 2018 Aug 14;7(8). pii: E216. doi: 10.3390/jcm7080216.

25.

Gene Suppression of Transketolase-Like Protein 1 (TKTL1) Sensitizes Glioma Cells to Hypoxia and Ionizing Radiation.

Heller S, Maurer GD, Wanka C, Hofmann U, Luger AL, Bruns I, Steinbach JP, Rieger J.

Int J Mol Sci. 2018 Jul 25;19(8). pii: E2168. doi: 10.3390/ijms19082168.

26.

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trial.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Res Clin Oncol. 2018 Aug;144(8):1581-1589. doi: 10.1007/s00432-018-2671-z. Epub 2018 May 28.

PMID:
29808316
27.

Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems.

Luger AL, Sauer B, Lorenz NI, Engel AL, Braun Y, Voss M, Harter PN, Steinbach JP, Ronellenfitsch MW.

Int J Mol Sci. 2018 May 17;19(5). pii: E1504. doi: 10.3390/ijms19051504.

28.

CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Zeiner PS, Zinke J, Kowalewski DJ, Bernatz S, Tichy J, Ronellenfitsch MW, Thorsen F, Berger A, Forster MT, Muller A, Steinbach JP, Beschorner R, Wischhusen J, Kvasnicka HM, Plate KH, Stefanović S, Weide B, Mittelbronn M, Harter PN.

Acta Neuropathol Commun. 2018 Mar 1;6(1):18. doi: 10.1186/s40478-018-0521-5.

29.

Suppression of oxidative phosphorylation confers resistance against bevacizumab in experimental glioma.

Eriksson JA, Wanka C, Burger MC, Urban H, Hartel I, von Renesse J, Harter PN, Mittelbronn M, Steinbach JP, Rieger J.

J Neurochem. 2018 Feb;144(4):421-430. doi: 10.1111/jnc.14264. Epub 2018 Jan 8.

30.

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

Burger MC, Breuer S, Cieplik HC, Harter PN, Franz K, Bähr O, Steinbach JP.

Int J Mol Sci. 2017 Nov 20;18(11). pii: E2469. doi: 10.3390/ijms18112469.

31.

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma.

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol. 2018 Jun 18;20(7):975-985. doi: 10.1093/neuonc/nox204.

32.

ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors.

Bähr O, Gross S, Harter PN, Kirches E, Mawrin C, Steinbach JP, Mittelbronn M.

Oncol Lett. 2017 Nov;14(5):5443-5451. doi: 10.3892/ol.2017.6832. Epub 2017 Aug 28.

33.

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.

Burger MC, Ronellenfitsch MW, Lorenz NI, Wagner M, Voss M, Capper D, Tzaridis T, Herrlinger U, Steinbach JP, Stoffels G, Langen KJ, Brandts C, Senft C, Harter PN, Bähr O.

Oncol Rep. 2017 Dec;38(6):3291-3296. doi: 10.3892/or.2017.6013. Epub 2017 Oct 2.

34.

Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.

Thiepold AL, Lorenz NI, Foltyn M, Engel AL, Divé I, Urban H, Heller S, Bruns I, Hofmann U, Dröse S, Harter PN, Mittelbronn M, Steinbach JP, Ronellenfitsch MW.

Brain. 2017 Oct 1;140(10):2623-2638. doi: 10.1093/brain/awx196.

PMID:
28969371
35.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part I: Clinical and network analysis approaches.

Rosenow F, van Alphen N, Becker A, Chiocchetti A, Deichmann R, Deller T, Freiman T, Freitag CM, Gehrig J, Hermsen AM, Jedlicka P, Kell C, Klein KM, Knake S, Kullmann DM, Liebner S, Norwood BA, Omigie D, Plate K, Reif A, Reif PS, Reiss Y, Roeper J, Ronellenfitsch MW, Schorge S, Schratt G, Schwarzacher SW, Steinbach JP, Strzelczyk A, Triesch J, Wagner M, Walker MC, von Wegner F, Bauer S.

Epilepsy Behav. 2017 Nov;76:13-18. doi: 10.1016/j.yebeh.2017.06.041. Epub 2017 Sep 13. Review.

PMID:
28917501
36.

Personalized translational epilepsy research - Novel approaches and future perspectives: Part II: Experimental and translational approaches.

Bauer S, van Alphen N, Becker A, Chiocchetti A, Deichmann R, Deller T, Freiman T, Freitag CM, Gehrig J, Hermsen AM, Jedlicka P, Kell C, Klein KM, Knake S, Kullmann DM, Liebner S, Norwood BA, Omigie D, Plate K, Reif A, Reif PS, Reiss Y, Roeper J, Ronellenfitsch MW, Schorge S, Schratt G, Schwarzacher SW, Steinbach JP, Strzelczyk A, Triesch J, Wagner M, Walker MC, von Wegner F, Rosenow F.

Epilepsy Behav. 2017 Nov;76:7-12. doi: 10.1016/j.yebeh.2017.06.040. Epub 2017 Sep 14. Review.

PMID:
28917498
37.

Bevacizumab as a last-line treatment for glioblastoma following failure of radiotherapy, temozolomide and lomustine.

Wenger KJ, Wagner M, You SJ, Franz K, Harter PN, Burger MC, Voss M, Ronellenfitsch MW, Fokas E, Steinbach JP, Bähr O.

Oncol Lett. 2017 Jul;14(1):1141-1146. doi: 10.3892/ol.2017.6251. Epub 2017 May 25.

38.

Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.

Capper D, von Deimling A, Brandes AA, Carpentier AF, Kesari S, Sepulveda-Sanchez JM, Wheeler HR, Chinot O, Cher L, Steinbach JP, Specenier P, Rodon J, Cleverly A, Smith C, Gueorguieva I, Miles C, Guba SC, Desaiah D, Estrem ST, Lahn MM, Wick W.

Int J Mol Sci. 2017 May 6;18(5). pii: E995. doi: 10.3390/ijms18050995.

39.

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.

Burger MC, Mildenberger IC, Wagner M, Mittelbronn M, Steinbach JP, Bähr O.

Int J Mol Sci. 2017 Mar 29;18(4). pii: E726. doi: 10.3390/ijms18040726.

40.

Intracellular pH measured by 31 P-MR-spectroscopy might predict site of progression in recurrent glioblastoma under antiangiogenic therapy.

Wenger KJ, Hattingen E, Franz K, Steinbach JP, Bähr O, Pilatus U.

J Magn Reson Imaging. 2017 Oct;46(4):1200-1208. doi: 10.1002/jmri.25619. Epub 2017 Feb 6.

PMID:
28165649
41.

Myoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.

Steidl E, Pilatus U, Hattingen E, Steinbach JP, Zanella F, Ronellenfitsch MW, Bähr O.

PLoS One. 2016 Dec 29;11(12):e0168113. doi: 10.1371/journal.pone.0168113. eCollection 2016.

42.

CASP9 germline mutation in a family with multiple brain tumors.

Ronellenfitsch MW, Oh JE, Satomi K, Sumi K, Harter PN, Steinbach JP, Felsberg J, Capper D, Voegele C, Durand G, McKay J, Le Calvez-Kelm F, Schittenhelm J, Klink B, Mittelbronn M, Ohgaki H.

Brain Pathol. 2018 Jan;28(1):94-102. doi: 10.1111/bpa.12471. Epub 2017 Apr 17.

PMID:
27935156
43.

FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.

Brucker DP, Maurer GD, Harter PN, Rieger J, Steinbach JP.

Int J Oncol. 2016 Dec;49(6):2399-2410. doi: 10.3892/ijo.2016.3760. Epub 2016 Nov 4.

PMID:
27840901
44.

Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis.

Antonietti P, Linder B, Hehlgans S, Mildenberger IC, Burger MC, Fulda S, Steinbach JP, Gessler F, Rödel F, Mittelbronn M, Kögel D.

Mol Cancer Ther. 2017 Jan;16(1):156-168. doi: 10.1158/1535-7163.MCT-16-0262. Epub 2016 Oct 24.

45.

Brain invasion in otherwise benign meningiomas does not predict tumor recurrence.

Baumgarten P, Gessler F, Schittenhelm J, Skardelly M, Tews DS, Senft C, Dunst M, Imoehl L, Plate KH, Wagner M, Steinbach JP, Seifert V, Mittelbronn M, Harter PN.

Acta Neuropathol. 2016 Sep;132(3):479-81. doi: 10.1007/s00401-016-1598-1. Epub 2016 Jul 27. No abstract available.

PMID:
27464983
46.

To diet or not to diet - that is still the question.

Rieger J, Steinbach JP.

Neuro Oncol. 2016 Aug;18(8):1035-6. doi: 10.1093/neuonc/now131. No abstract available.

47.

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.

Burger MC, Zeiner PS, Jahnke K, Wagner M, Mittelbronn M, Steinbach JP.

PLoS One. 2016 Jun 2;11(6):e0155315. doi: 10.1371/journal.pone.0155315. eCollection 2016.

48.

Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.

Schaub C, Tichy J, Schäfer N, Franz K, Mack F, Mittelbronn M, Kebir S, Thiepold AL, Waha A, Filmann N, Banat M, Fimmers R, Steinbach JP, Herrlinger U, Rieger J, Glas M, Bähr O.

J Neurooncol. 2016 Aug;129(1):93-100. doi: 10.1007/s11060-016-2144-7. Epub 2016 May 18.

PMID:
27193554
49.

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Genßler S, Burger MC, Zhang C, Oelsner S, Mildenberger I, Wagner M, Steinbach JP, Wels WS.

Oncoimmunology. 2015 Dec 21;5(4):e1119354. eCollection 2016 Apr.

50.

Activation of AMP-activated kinase modulates sensitivity of glioma cells against epidermal growth factor receptor inhibition.

Hartel I, Ronellenfitsch M, Wanka C, Wolking S, Steinbach JP, Rieger J.

Int J Oncol. 2016 Jul;49(1):173-80. doi: 10.3892/ijo.2016.3498. Epub 2016 Apr 25.

PMID:
27121290

Supplemental Content

Loading ...
Support Center